While ApolloQD may sound like something out of a sci-fi novel, we're not just throwing words up in the air. Researchers at MIT did a study using QDs for vaccine delivery and were able to obtain success rates of 92% and 97%. With these stats in mind and the fact that our technology is more intricate, we can safely say that ApolloQD aims for a 90% success rate in each country we expand to in Phase 2. But this is expected to increase once more research, clinical trials, and development is done.
In Phase 2 of ApolloQD, we plan on expanding to Ethiopia, Colombia, and Cyprus due the to fact that they have relatively high death rates due to leukemia. Knowing that our aim is 90% success in each Phase 2 Location, we would be targeting to save around 7,000 patients in Phase 2.
This number was a result of calculating 90% of each country's annual leukemia average which was obtained from the World Health Organization's data sets.
ApolloQD is a moonshot and therefore, will take some time to get off the ground but we are already thinking long term to ensure success.
Recognizing the disparities in health care systems globally, we plan to expand to countries with some of the highest death rates due to leukemia.
Cancer therapy is no simple thing.
Each treatment depends individually on the patient and because of this we cannot give accurate quantified prices on ApolloQD's treatment.
What we can say is that it will be much more effective and much cheaper. Our processing will use different raw materials, resulting in production costs of the QD to drop by 80%.
This is why we plan on expanding to developing countries specifically; closing the gap in health care system is very important to our team personally.
Copyright © 2022 Apollo Therapeutics - All Rights Reserved.